A Phase 2 interventional study of Tonlamarsen and Placebo in Hypertension, sponsored by Kardigan, Inc.. Completed at 39 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-31.
Sponsored by Kardigan, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,031 studies in Hypertension with a site in United States — 272 open to participants now, 369 under way, 16 of them phase 3. Hypertension · United States.
Among the 2,031 studies in Hypertension with a site in United States, this one is the 613th largest by enrollment of the 1,779 interventional ones that give a count, is one of 99 that started in 2025, is one of 170 in phase 2, and was the 1,860th registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →272 of the 2,031 studies in Hypertension with a site in United States are open now. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18+
University of Alabama at Birmingham · Sites in United States
Ages 16–56 · Women only
The University of Texas at Arlington · Sites in United States
Ages 26–49
CRISPR Therapeutics AG · Sites in United States, Australia, United Kingdom
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,031 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 147 · Phase 2 216 · Phase 3 214 · Phase 4 188
First in 1973; this study’s year is marked. 99 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 206 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 100 across the 1,779 interventional studies, 200 across the 238 observational. Of the 1,514 that completed or were terminated, 578 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
461 of 2,031 have an industry lead sponsor. The 10 most frequent:
Kardigan, Inc. is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
Kardigan, Inc. has 2 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
143 of the studies in Hypertension with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT04971720Phase 3University of Alabama at BirminghamPRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis | 2027-01-01 |
| NCT06948422Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) | 2027-09 |
| NCT06948435Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 | 2027-09 |
| NCT06952530Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 | 2027-09 |
Add all 143 to your calendar (.ics) → With an account.
Among the 2,031 studies in Hypertension with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the blood pressure (BP)-lowering efficacy of tonlamarsen in adult participants who, despite taking 2 or more antihypertensive medications, have not achieved their target blood pressure (BP).
Key Inclusion Criteria:
Key Exclusion Criteria:
1 dose of placebo and 5 doses of active drug will be administered by subcutaneous (SC) injection
Drug: Tonlamarsen
5 doses of placebo and 1 dose of active drug will be administered by subcutaneous (SC) injection
Drug: Placebo
Tonlamarsen will be administered subcutaneously (SC) every 4 weeks during the randomized part of the study
Placebo will be administered subcutaneously (SC) every 4 weeks during the randomized part of the study
To assess the effect of tonlamarsen on plasma angiotensinogen (AGT) levels
Percent Change from baseline (Week 0) in plasma angiotensinogen (AGT) levels to Week 20
Time frame: Week 20
To assess the systolic blood pressure-lowering efficacy of tonlamarsen
Change from baseline (Week 0) in mean office seated systolic blood pressure to Week 20
Time frame: Week 20
To assess the safety and tolerability of tonlamarsen
Incidence and severity of treatment emergent adverse events (TEAEs). Incidence of clinically significant abnormalities in laboratory assessments, ECGs and vital signs. Incidence of: (1) Hyperkalemia, defined as serum potassium \>5.5 mmol/L. (2) Hypotension, defined as systolic blood pressure \<90 mmHg, or systolic blood pressure \<100 mmHg and symptomatic and/or requiring clinical intervention. (3) Renal dysfunction, defined as a decrease of eGFR \>30% from baseline value. (4) Increased proteinuria, defined as UPCR \>0.5 mg/mg from baseline value.
Time frame: Week 28
To assess the efficacy of tonlamarsen in achieving office seated systolic blood pressure <130 mmHg
Proportion of participants with mean office seated systolic blood pressure \<130 mmHg at Week 20
Time frame: Week 20
To assess the systolic blood pressure-lowering efficacy of tonlamarsen
Change from baseline (Week 0) in mean self-assessed home systolic blood pressure through Week 20
Time frame: Week 20
To assess the effect of tonlamarsen on severe systolic blood pressure elevations
Proportion of participants with any daily average home systolic blood pressure ≥150 mmHg at Week 20
Time frame: Week 20
To assess the diastolic blood pressure-lowering efficacy of tonlamarsen
Change from baseline (Week 0) in mean office seated diastolic blood pressure to Week 20
Time frame: Week 20
Plan to share: No
Ran from Apr 2025 to primary completion in Jan 2026, 9 months.
Of 56 industry-sponsored phase 2 interventional studies under Hypertension, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's 9 months is below that.
Counting every sponsor, half of 110 studies reached it within 25 months; a quarter within 11 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tonlamarsen
Kardigan, Inc.